ChinaHealthcare and life sciences2026 – ongoingAkeso
AI-supported antibody and personalized vaccine discovery
Akeso advanced an AI-developed antibody into 7 Phase II trials
Problem
Akeso needed to develop antibody candidates and select mutations for personalized cancer vaccines.
Approach
Akeso used its proprietary AI drug-discovery platform to develop AK139, a bispecific antibody targeting IL-4Rα and ST2. It also used AI to select immunogenic mutations for AK154, a personalized mRNA cancer vaccine undergoing a Phase I pancreatic-cancer study.
Results
Takeaway
The platform produced candidates that reached clinical development. Akeso did not disclose a measured reduction in discovery time or establish clinical benefit attributable to AI.
Categories
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Product and service innovationProcess innovation
- AI technology
- Predictive analytics and ML
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
Akeso identified AK139 as a product of its AI discovery platform and reported seven Phase II trials. It also described AI mutation selection for AK154 and an ongoing Phase I study.
Full details are in the original sources.